A Quarterly Injection Cut Acute Pancreatitis Attacks by 78 Percent in Adults with Dangerously High Triglycerides

Two Phase 3 trials of plozasiran cut triglycerides by about 80% and reduced acute pancreatitis events by 78%. An FDA filing is expected by year-end.

Have A Referral?